Here, the total anti-HEV seroprevalence (18.70%) exceeded previously reported HEV coinfection rates in patients with CHB (2.8%–17.6%) (Nasir and Wu, 2020) and was substantially higher than recent observations in Hebei’s student population (IgG+: 3.4%, IgM+/IgG+: 0.2%) in 2024 and the occupational (IgG+: 13.3%, IgM+: 0.67%) population (Liu et al., 2024). This evidence concerns the gene CD40LG and coinfection.